May 10, 2024 11:22 AM EDT
R&D
News Briefing

iTeos to raise $120M; Xbrane and STA­DA to out-li­cense Lu­cen­tis biosim­i­lar

ENDPOINTS

Plus, news about Anap­tys­Bio, Alza­mend, AEON Bio­phar­ma and ar­genx:

iTeos Ther­a­peu­tics’ $120M of­fer­ing: The im­muno-on­col­o­gy com­pa­ny

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times